Objectives To investigate the efficacy and safety of switching from infliximab reference
product (RP) to its biosimilar or maintaining biosimilar treatment in patients with ankylosing …

(1) To compare the serum levels of Dickkopf-1 (DKK-1) and bone biomarkers in patients
with ankylosing spondylitis (AS) and healthy controls. (2) To examine the effects of anti-tumor …

Objective To demonstrate pharmacokinetic equivalence of CT-P10 and innovator rituximab (RTX)
in patients with rheumatoid arthritis (RA) with inadequate responses or intolerances to …

Osteoporosis in rheumatic diseases is a very well-known complication. Systemic inflammation
results in both generalized and localized bone loss and erosions. Recently, increased …

Background CT-P10 is a biosimilar candidate of innovator rituximab (RTX) that demonstrated
a comparable clinical profile to RTX in a phase I randomized controlled trial (RCT) in …

The aim of this study was to determine whether skin temperature measurement by digital
thermography on hands and feet is useful for diagnosis of Raynaud's phenomenon (RP). Fifty-…

Early differentiation between bacterial infections and disease flares in autoimmune disease
patients is important due to different treatments. Seventy-nine autoimmune disease patients …

As the prevalence of gout and hyperuricemia increases, the comorbidities of gout and
hyperuricemia have become a public health burden. In particular, risks of cardiovascular disease (…

Background CT-P10 is a biosimilar of innovator rituximab (RTX), a biological therapy used
to treat patients with rheumatoid arthritis (RA) who have responded inadequately to anti-tumor …

Axial spondyloarthritis (axSpA) is a chronic inflammatory disease that primarily affects the
axial joints. Altered bone metabolism associated with chronic inflammation leads to both new …